We conducted an in vivo stress test wherein the CAR-T cell dosage was reduced to functional limits, requiring these cells to persist without immune exhaustion to eradicate tumor cells to confirm the synergistic effect of CHZ868 on CD19 CAR-T cells in vivo. Here, CD19 is linked to neoplasm.